This review describes three clinical scenarios: preoperative stabilization and bridge-to-surgery, planned intraoperative support in patients at high risk of perioperative low cardiac output, and rescue support for failure to wean from cardiopulmonary bypass or postoperative heart failure.
Abstract
Temporary mechanical circulatory support (tMCS) has evolved as a first-line treatment of cardiogenic shock refractory to medical therapy. In recent years, tMCS has been applied to bridge and precondition end-stage heart failure patients with structural heart disease for surgery or intervention. This review describes three clinical scenarios: preoperative stabilization and bridge-to-surgery (Type 1), planned intraoperative support in patients at high risk of perioperative low cardiac output (Type 2), and rescue support for failure to wean from cardiopulmonary bypass or postoperative heart failure (Type 3). PubMed/MEDLINE was searched for publications from January 2017 onward. It discusses microaxial flow pumps (mAFP), intra-aortic balloon pumps (IABP), veno-arterial extracorporeal life support (VA-ECLS), and combined strategies, including left ventricular unloading during VA-ECLS. Clinical applications include acute myocardial infarction-related cardiogenic shock, acute mitral regurgitation, post-infarction ventricular septal defect and advanced heart failure therapy. Current European and American recommendations support early, individualized and Heart Team-guided use in selected patients. In this review, we aim to summarize the important aspects of protected tMCS implementation in cardiac surgery and highlight some recent evidence in this field.
Cardiogenic shock remains the leading cause of death in patients with acute myocardial infarction and severe acute heart failure. Temporary mechanical circulatory support devices have emerged as important adjuncts for restoring systemic perfusion, unloading the failing ventricle, and stabilizing patients for cardiogeni...
Holger Thiele, S. von der Emde, A. Freund· Circulation: Heart Failure· 0 citations
Current evidence on device-specific physiology, escalation and weaning, pulmonary vascular considerations, and post-transplant outcomes are summarized, and an integrated framework for individualized, trajectory-based decision-making is proposed.
Jorge A Ortega-Hernández, L. Baldetti, G. Gallone et al.· Current Heart Failure Report...· 0 citations
The Impella 5.5 is a surgically implanted micro-axial left ventricular assist device (LVAD) increasingly utilized for mechanical circulatory support (MCS) in cardiogenic shock. While typically used for acute support up to FDA-approved 14 days, reports of prolonged utilization remain limited. We present the case of a 69...
J. Shimamura, A. Levine, Stephen Pan et al.· Artificial Organs· 1 citation
The use of the intra-aortic balloon pump (IABP) in advanced heart failure (HF) and cardiogenic shock (CS) is still under debate. In this study we sought to assess the clinical and hemodynamic outcomes in IABP-treated heart transplantation (HTx) patients as well as its impact on mortality. We retrospectively analyzed pa...
V. Bellini, Daniel Fatori, Fernanda Tamura et al.· Cardiology and Cardiovascula...· 0 citations
Abstract Aims Right ventricular dysfunction (RVD) is common in cardiogenic shock (CS) due to left ventricular failure and is associated with increased mortality, but its impact in patients requiring temporary mechanical circulatory support (tMCS) remains unclear. We explored RVD and its association with clinical outcom...
Jan Estoppey, Iulia-Maia Muresan, Matthias Bossard et al.· European Heart Journal Open· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.